Drug Profile
p47/gp91 gene therapy - Nexell Therapeutics
Latest Information Update: 06 Aug 2003
Price :
$50
*
At a glance
- Originator Nexell Therapeutics [CEASED]
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological disorders